|
Market Cap (20-May) $4,758,880 (1,313th) |
Close (30-Jun) $1.51 |
Volume (30-Jun) 12,937 |
Shortsold (8-Aug) 2,108 (0.02%) (508th) |
|
52w High $1.09 |
52w Low $0.280 |
P/E - |
EPS -0.42 |
ZLD released this announcement to the ASX on 13 January 2022, 12:09. The announcement is not marked as price sensitive, and is 22 page(s) in length and 11.29MB in size.
You can view all announcements from ZLD and see how they appear on a price chart on the announcements page.
At the date of this announcement, ZLD was 0.031% short sold according to ASIC data. It was ranked the 485th most shorted stock on the ASX. It remains ranked 508th as of the latest reported data (08 August 2024).
| Other Recent Announcements from ZLD | |
|---|---|
| Amendment to ASX announcement - Zelira's diabetic nerve pai | 8 June 2023, 9:47 |
| Initial Director's Interest Notice | 1 June 2023, 15:29 |
| Final Director's Interest Notice | 1 June 2023, 15:27 |
| 2021 Annual General Meeting Presentation | 13 January 2022, 12:09 |
| Zelira receives $1.2 million cash R&D Tax Incentive | 12 January 2022, 9:21 |
| Partial Receipt Of Zeliras EDCDM Technology License Fee | 10 January 2022, 8:49 |
| ZLDs Phase 1 pain trial published in peer-reviewed journal | 23 December 2021, 8:20 |
You must be logged in to post a reply.
Zelira Therapeutics 